Safe, effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed in children younger than 12 years of age. In this article the authors present results for 5-to-11-year-old children.

The objective of this double-blind randomised controlled trial was to compare propranolol and topiramate in terms of tolerability and efficacy in preventing chronic migraine over 24 weeks.

This randomized, double-blind, placebo-controlled phase 2 clinical trial investigated the potential therapeutic value of losartan, an angiotensin II receptor antagonist, in reducing whole brain volume atrophy in patients with mild-to moderate Alzheimer’s disease.

Registration is now open for the OneNeurology European Summit, taking place virtually on Friday, 17 December.

With so few chances for EAN staff and members to meet in person, we decided to introduce the team behind the scenes. This time it's Florian, our Congress Manager, and Helene, from the Education Department.

The EAN Spring School is available to 120 clinical neurologists in training who have not yet completed their residency or clinical speciality training.

The EAN Education Committee has received numerous applications for the 2022 Research Fellowship and we are happy to announce and introduce the recipients below.

EAN President, Claudio Bassetti gives some deep insights into the EAN's recent advocacy activity and plans for the future.

Our research paper of the month is an open-label, single-arm, phase II futility trial exploring the safety and the effect of treatment with the antimalarial drug hydroxychloroquine on disability worsening in patients with primary progressive multiple sclerosis.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.

The Austrian Society of Neurology (ÖGN - Österreichische Gesellschaft für Neurologie) will hold its 19th annual meeting in March 2022 as a physical event in Graz, Austria.

After almost two years of planning and three digital events, the first ever, in-person Brain Innovation Days, led by the European Brain Council, took place on 12-13 October 2021 in Brussels, Belgium.

Alzheimer Europe is delighted to have co-authored a new paper, published in the journal Alzheimer's Research & Therapy, called ‘Dementia risk communication. A user manual for Brain Health Services’.

In November 2021, the European Pain Federation and Pain Alliance Europe organised the annual SIP forum. For the second year in a row, we met virtually due to the COVID-19 pandemic.

Read the latest reports on EAN clinical fellowships in Innsbruck (AT) and Linz (AT)